ID   FGFR3_HUMAN             Reviewed;         694 AA.
AC   P22607-3;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   12-OCT-2022, entry version 255.
DE   RecName: Full=Isoform 3 of Fibroblast growth factor receptor 3;
DE            Short=FGFR-3;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD333;
DE   Flags: Precursor;
GN   Name=FGFR3; Synonyms=JTK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1847508; DOI=10.1073/pnas.88.4.1095;
RA   Keegan K., Johnson D.E., Williams L.T., Hayman M.J.;
RT   "Isolation of an additional member of the fibroblast growth factor receptor
RT   family, FGFR-3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBUNIT, FGF1- AND
RP   FGF2-BINDING, SUBCELLULAR LOCATION, GLYCOSYLATION, AND DIMERIZATION.
RC   TISSUE=Squamous cell carcinoma;
RX   PubMed=11703096; DOI=10.1006/mcbr.2001.0306;
RA   Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H.,
RA   Kurokawa-Seo M.;
RT   "Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane
RT   domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs.";
RL   Mol. Cell Biol. Res. Commun. 4:365-373(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384; THR-441;
RP   THR-717 AND PHE-726.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=1664411; DOI=10.1016/0888-7543(91)90041-c;
RA   Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F.,
RA   Housman D.E., Wasmuth J.J.;
RT   "A gene encoding a fibroblast growth factor receptor isolated from the
RT   Huntington disease gene region of human chromosome 4.";
RL   Genomics 11:1133-1142(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 614-681.
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Colon tumor;
RX   PubMed=7923141;
RA   Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.;
RT   "Identification of a novel variant form of fibroblast growth factor
RT   receptor 3 (FGFR3 IIIb) in human colonic epithelium.";
RL   Cancer Res. 54:5206-5211(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Keratinocyte;
RX   PubMed=7495869; DOI=10.1016/0167-4781(95)00156-b;
RA   Scotet E., Houssaint E.;
RT   "The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is
RT   not strictly tissue-specific.";
RL   Biochim. Biophys. Acta 1264:238-242(1995).
RN   [11]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F.,
RA   Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [12]
RP   INVOLVEMENT IN SADDAN, VARIANT SADDAN MET-650, AND CHARACTERIZATION OF
RP   VARIANT SADDAN MET-650.
RX   PubMed=10053006; DOI=10.1086/302275;
RA   Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E.,
RA   McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J.,
RA   Donoghue D.J., Thompson L.M., Francomano C.A.;
RT   "A novel skeletal dysplasia with developmental delay and acanthosis
RT   nigricans is caused by a Lys650Met mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   Am. J. Hum. Genet. 64:722-731(1999).
RN   [13]
RP   FUNCTION AS FGF9 RECEPTOR IN CHONDROCYTES AND IN ACTIVATION OF SIGNALING
RP   PATHWAYS, SUBUNIT, SUBCELLULAR LOCATION, DEGRADATION, AUTOPHOSPHORYLATION,
RP   AND CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=10611230; DOI=10.1128/mcb.20.2.516-522.2000;
RA   Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A.;
RT   "The transmembrane mutation G380R in fibroblast growth factor receptor 3
RT   uncouples ligand-mediated receptor activation from down-regulation.";
RL   Mol. Cell. Biol. 20:516-522(2000).
RN   [14]
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION; PHOSPHORYLATION OF PIK3R1;
RP   PTPN11/SHP2; STAT1; STAT3 AND MAP KINASES, PHOSPHORYLATION AT TYR-724,
RP   MUTAGENESIS OF TYR-577; TYR-724; TYR-760 AND TYR-770, AND CHARACTERIZATION
RP   OF VARIANT GLU-650.
RX   PubMed=11294897; DOI=10.1091/mbc.12.4.931;
RA   Hart K.C., Robertson S.C., Donoghue D.J.;
RT   "Identification of tyrosine residues in constitutively activated fibroblast
RT   growth factor receptor 3 involved in mitogenesis, Stat activation, and
RT   phosphatidylinositol 3-kinase activation.";
RL   Mol. Biol. Cell 12:931-942(2001).
RN   [15]
RP   UBIQUITINATION, PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   LYS-508, CHARACTERIZATION OF VARIANT ACH ARG-380, AND CHARACTERIZATION OF
RP   VARIANT TD2 GLU-650.
RX   PubMed=12297284; DOI=10.1016/s0014-5793(02)03255-6;
RA   Monsonego-Ornan E., Adar R., Rom E., Yayon A.;
RT   "FGF receptors ubiquitylation: dependence on tyrosine kinase activity and
RT   role in downregulation.";
RL   FEBS Lett. 528:83-89(2002).
RN   [16]
RP   FUNCTION AS PROTO-ONCOGENE IN ACTIVATION OF SIGNALING AND CELL
RP   PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF
RP   VARIANT GLU-650, AND AUTOPHOSPHORYLATION.
RX   PubMed=14534538; DOI=10.1038/sj.onc.1206798;
RA   Agazie Y.M., Movilla N., Ischenko I., Hayman M.J.;
RT   "The phosphotyrosine phosphatase SHP2 is a critical mediator of
RT   transformation induced by the oncogenic fibroblast growth factor receptor
RT   3.";
RL   Oncogene 22:6909-6918(2003).
RN   [17]
RP   INTERACTION WITH FGF1; FGF8; FGF9; FGF17; FGF18; FGF19 AND FGF20, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.m601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The complete
RT   mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [18]
RP   INTERACTION WITH SOCS1 AND SOCS3, FUNCTION IN ACTIVATION OF STAT1 AND MAP
RP   KINASES, GLYCOSYLATION, PHOSPHORYLATION, MUTAGENESIS OF LYS-508, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16410555; DOI=10.1242/jcs.02740;
RA   Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.;
RT   "Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and
RT   modulate fibroblast growth factor receptor signaling.";
RL   J. Cell Sci. 119:380-387(2006).
RN   [19]
RP   FUNCTION IN REGULATION OF CHONDROCYTE PROLIFERATION AND IN ACTIVATION OF
RP   PLCG1 AND STAT1, INTERACTION WITH FHF1 AND HEPARIN, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION, AND CHARACTERIZATION OF VARIANTS ARG-380; GLU-650 AND
RP   MET-650.
RX   PubMed=17561467; DOI=10.1016/j.bone.2006.11.030;
RA   Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y.,
RA   Tanaka H.;
RT   "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic
RT   dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via
RT   PLCgamma-activated STAT1.";
RL   Bone 41:273-281(2007).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF CBL, UBIQUITINATION, GLYCOSYLATION,
RP   SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND CHARACTERIZATION OF VARIANTS
RP   CYS-248; CYS-373 AND MET-650.
RX   PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x;
RA   Bonaventure J., Horne W.C., Baron R.;
RT   "The localization of FGFR3 mutations causing thanatophoric dysplasia type I
RT   differentially affects phosphorylation, processing and ubiquitylation of
RT   the receptor.";
RL   FEBS J. 274:3078-3093(2007).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF VARIANT GLU-650,
RP   ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=17145761; DOI=10.1074/jbc.m606144200;
RA   Krejci P., Masri B., Salazar L., Farrington-Rock C., Prats H.,
RA   Thompson L.M., Wilcox W.R.;
RT   "Bisindolylmaleimide I suppresses fibroblast growth factor-mediated
RT   activation of Erk MAP kinase in chondrocytes by preventing Shp2 association
RT   with the Frs2 and Gab1 adaptor proteins.";
RL   J. Biol. Chem. 282:2929-2936(2007).
RN   [22]
RP   INTERACTION WITH FGF19; FGF21 AND KLB.
RX   PubMed=17623664; DOI=10.1074/jbc.m704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V.,
RA   Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [23]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the
RT   Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [24]
RP   FUNCTION IN ACTIVATION OF STAT1; STAT5; MAPK1/ERK2; MAPK3/ERK1 AND THE MAP
RP   KINASE SIGNALING PATHWAY.
RX   PubMed=19088846; DOI=10.1371/journal.pone.0003961;
RA   Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A.,
RA   Thompson L.M., Bryja V., Kozubik A., Wilcox W.R.;
RT   "Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal
RT   dysplasia undermines dominant role of STAT1 in FGFR3 signaling in
RT   cartilage.";
RL   PLoS ONE 3:E3961-E3961(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   FUNCTION, INTERACTION WITH PIK3R1 AND PLCG1, AND PHOSPHORYLATION AT
RP   TYR-760.
RX   PubMed=19286672; DOI=10.1093/hmg/ddp116;
RA   Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D.,
RA   Wilcox W.R., Thompson L.M.;
RT   "A novel interaction between fibroblast growth factor receptor 3 and the
RT   p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation
RT   of ERK by p85 in multiple myeloma cells.";
RL   Hum. Mol. Genet. 18:1951-1961(2009).
RN   [27]
RP   REVIEW ON FUNCTION; ALTERNATIVE SPLICING; SIGNALING AND ROLE IN DISEASE.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [28]
RP   REVIEW ON FUNCTION; LIGANDS; SIGNALING; ALTERNATIVE SPLICING; DOMAIN; ROLE
RP   IN DISEASE; UBIQUITINATION AND DEGRADATION.
RX   PubMed=15748888; DOI=10.1016/j.yexcr.2004.11.012;
RA   L'Hote C.G., Knowles M.A.;
RT   "Cell responses to FGFR3 signalling: growth, differentiation and
RT   apoptosis.";
RL   Exp. Cell Res. 304:417-431(2005).
RN   [29]
RP   REVIEW ON ROLE IN SKELETON DEVELOPMENT AND DISEASE.
RX   PubMed=19066716; DOI=10.1007/s00774-008-0009-7;
RA   Harada D., Yamanaka Y., Ueda K., Tanaka H., Seino Y.;
RT   "FGFR3-related dwarfism and cell signaling.";
RL   J. Bone Miner. Metab. 27:9-15(2009).
RN   [30]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1,
RP   ACTIVITY REGULATION, AND DOMAIN.
RX   PubMed=14732692; DOI=10.1073/pnas.0307287101;
RA   Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A.,
RA   Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.;
RT   "Insights into the molecular basis for fibroblast growth factor receptor
RT   autoinhibition and ligand-binding promiscuity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004).
RN   [33]
RP   VARIANT ACH ARG-380.
RX   PubMed=8078586; DOI=10.1038/371252a0;
RA   Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M.,
RA   Maroteaux P., le Merrer M., Munnich A.;
RT   "Mutations in the gene encoding fibroblast growth factor receptor-3 in
RT   achondroplasia.";
RL   Nature 371:252-254(1994).
RN   [34]
RP   VARIANT ACH ARG-380.
RX   PubMed=7847369;
RA   Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A.,
RA   Machado M., Kaitila I., McIntosh I., Francomano C.A.;
RT   "Achondroplasia is defined by recurrent G380R mutations of FGFR3.";
RL   Am. J. Hum. Genet. 56:368-373(1995).
RN   [35]
RP   VARIANT ACH CYS-375.
RX   PubMed=7758520; DOI=10.1007/bf01954274;
RA   Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A.,
RA   Gitzelmann R., Steinmann B.;
RT   "A glycine 375-to-cysteine substitution in the transmembrane domain of the
RT   fibroblast growth factor receptor-3 in a newborn with achondroplasia.";
RL   Eur. J. Pediatr. 154:215-219(1995).
RN   [36]
RP   VARIANT TD1 CYS-249.
RX   PubMed=8589699; DOI=10.1093/hmg/4.11.2175;
RA   Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R., Wasmuth J.J.;
RT   "Another mutation that results in the substitution of an unpaired cysteine
RT   residue in the extracellular domain of FGFR3 in thanatophoric dysplasia
RT   type I.";
RL   Hum. Mol. Genet. 4:2175-2177(1995).
RN   [37]
RP   VARIANTS TD1 CYS-248 AND CYS-371, AND VARIANT TD2 GLU-650.
RX   PubMed=7773297; DOI=10.1038/ng0395-321;
RA   Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J.,
RA   Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.;
RT   "Thanatophoric dysplasia (types I and II) caused by distinct mutations in
RT   fibroblast growth factor receptor 3.";
RL   Nat. Genet. 9:321-328(1995).
RN   [38]
RP   VARIANT HYPOCHONDROPLASIA LYS-540.
RX   PubMed=7670477; DOI=10.1038/ng0795-357;
RA   Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I.,
RA   Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.;
RT   "A recurrent mutation in the tyrosine kinase domain of fibroblast growth
RT   factor receptor 3 causes hypochondroplasia.";
RL   Nat. Genet. 10:357-359(1995).
RN   [39]
RP   VARIANT CAN GLU-391.
RX   PubMed=7493034; DOI=10.1038/ng1295-462;
RA   Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.;
RT   "Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in
RT   Crouzon syndrome with acanthosis nigricans.";
RL   Nat. Genet. 11:462-464(1995).
RN   [40]
RP   CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=8599935; DOI=10.1002/j.1460-2075.1996.tb00384.x;
RA   Webster M.K., Donoghue D.J.;
RT   "Constitutive activation of fibroblast growth factor receptor 3 by the
RT   transmembrane domain point mutation found in achondroplasia.";
RL   EMBO J. 15:520-527(1996).
RN   [41]
RP   VARIANTS TD1 CYS-248; CYS-249; CYS-370 AND CYS-373.
RX   PubMed=8845844; DOI=10.1093/hmg/5.4.509;
RA   Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L.,
RA   le Merrer M., Munnich A., Bonaventure J.;
RT   "Missense FGFR3 mutations create cysteine residues in thanatophoric
RT   dwarfism type I (TD1).";
RL   Hum. Mol. Genet. 5:509-512(1996).
RN   [42]
RP   CHARACTERIZATION OF VARIANT TD2 GLU-650, CHARACTERIZATION OF VARIANT
RP   GLN-650, AND PHOSPHORYLATION AT TYR-647 AND TYR-648.
RX   PubMed=8754806; DOI=10.1128/mcb.16.8.4081;
RA   Webster M.K., D'Avis P.Y., Robertson S.C., Donoghue D.J.;
RT   "Profound ligand-independent kinase activation of fibroblast growth factor
RT   receptor 3 by the activation loop mutation responsible for a lethal
RT   skeletal dysplasia, thanatophoric dysplasia type II.";
RL   Mol. Cell. Biol. 16:4081-4087(1996).
RN   [43]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9042914;
RA   Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K., Whitaker L.A.,
RA   Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N., Mulvihill J.J.,
RA   Losken H.W., Mulliken J.B., Guttmacher A.E., Wilroy R.S., Clarke L.A.,
RA   Hollway G., Ades L.C., Haan E.A., Mulley J.C., Cohen M.M. Jr., Bellus G.A.,
RA   Francomano C.A., Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.;
RT   "A unique point mutation in the fibroblast growth factor receptor 3 gene
RT   (FGFR3) defines a new craniosynostosis syndrome.";
RL   Am. J. Hum. Genet. 60:555-564(1997).
RN   [44]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND MET-650.
RX   PubMed=9207791; DOI=10.1038/ng0797-260;
RA   Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M.,
RA   Bergsagel P.L.;
RT   "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is
RT   associated with increased expression and activating mutations of fibroblast
RT   growth factor receptor 3.";
RL   Nat. Genet. 16:260-264(1997).
RN   [45]
RP   VARIANT TD1 CYS-370.
RX   PubMed=9790257; DOI=10.1507/endocrj.45.suppl_s171;
RA   Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A.,
RA   Nimura A., Horikawa R., Tanaka T.;
RT   "G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric
RT   dysplasia.";
RL   Endocr. J. 45:S171-S174(1998).
RN   [46]
RP   VARIANT HYPOCHONDROPLASIA VAL-538.
RX   PubMed=10215410;
RA   Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E.,
RA   Anvret M.;
RT   "A novel missense mutation Ile538Val in the fibroblast growth factor
RT   receptor 3 in hypochondroplasia.";
RL   Hum. Mutat. 11:333-333(1998).
RN   [47]
RP   VARIANT HYPOCHONDROPLASIA THR-540.
RX   PubMed=9452043; DOI=10.1002/humu.1380110122;
RA   Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M., Bakker E.;
RT   "Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine
RT   kinase domain causing hypochondroplasia.";
RL   Hum. Mutat. Suppl. 1:S62-S65(1998).
RN   [48]
RP   VARIANT TD1 MET-650.
RX   PubMed=10671061;
RA   Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.;
RT   "Lys650Met substitution in the tyrosine kinase domain of the fibroblast
RT   growth factor receptor gene causes thanatophoric dysplasia type I.";
RL   Hum. Mutat. 12:362-363(1998).
RN   [49]
RP   VARIANT ARG-250.
RX   PubMed=9525367; DOI=10.1016/s0140-6736(98)24012-8;
RA   Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J.,
RA   Mulley J.C.;
RT   "Deafness due to Pro250Arg mutation of FGFR3.";
RL   Lancet 351:877-878(1998).
RN   [50]
RP   VARIANTS TD1 CYS-248; CYS-249 AND CYS-373.
RX   PubMed=10360402;
RX   DOI=10.1002/(sici)1096-8628(19990611)84:5<476::aid-ajmg12>3.0.co;2-x;
RA   Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B.,
RA   Wilcox W.R.;
RT   "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by
RT   FGFR3 mutations.";
RL   Am. J. Med. Genet. 84:476-480(1999).
RN   [51]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9950359;
RA   Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J.,
RA   Renier D.;
RT   "Sex related expressivity of the phenotype in coronal craniosynostosis
RT   caused by the recurrent P250R FGFR3 mutation.";
RL   J. Med. Genet. 36:9-13(1999).
RN   [52]
RP   VARIANTS BLC CYS-248; CYS-249; CYS-370 AND GLU-650, AND VARIANTS CERCA
RP   CYS-248; CYS-249; CYS-370 AND GLU-650.
RX   PubMed=10471491; DOI=10.1038/12615;
RA   Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S., Bourdin J.,
RA   Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.;
RT   "Frequent activating mutations of FGFR3 in human bladder and cervix
RT   carcinomas.";
RL   Nat. Genet. 23:18-20(1999).
RN   [53]
RP   VARIANT HYPOCHONDROPLASIA GLN-650.
RX   PubMed=11055896; DOI=10.1086/316892;
RA   Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T.,
RA   Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J.,
RA   Francomano C.A.;
RT   "Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor
RT   kinase activation and the severity of the skeletal dysplasia phenotype.";
RL   Am. J. Hum. Genet. 67:1411-1421(2000).
RN   [54]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=10777366; DOI=10.1136/jmg.37.3.220;
RA   Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G., De Paepe A.;
RT   "Clinical and radiographic features of a family with hypochondroplasia
RT   owing to a novel asn540ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   J. Med. Genet. 37:220-224(2000).
RN   [55]
RP   VARIANT MNKS ARG-250.
RX   PubMed=11746040; DOI=10.1002/ajmg.10049;
RA   Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.;
RT   "Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel
RT   shoulder with and without Pro250Arg mutation in the FGFR3 gene.";
RL   Am. J. Med. Genet. 104:112-119(2001).
RN   [56]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248.
RX   PubMed=11529856; DOI=10.1046/j.1365-2141.2001.02957.x;
RA   Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T.,
RA   Neri A.;
RT   "Analysis of FGFR3 gene mutations in multiple myeloma patients with
RT   t(4;14).";
RL   Br. J. Haematol. 114:362-364(2001).
RN   [57]
RP   VARIANT COLORECTAL CANCER LYS-322.
RX   PubMed=11325814;
RA   Jang J.-H., Shin K.-H., Park J.-G.;
RT   "Mutations in fibroblast growth factor receptor 2 and fibroblast growth
RT   factor receptor 3 genes associated with human gastric and colorectal
RT   cancers.";
RL   Cancer Res. 61:3541-3543(2001).
RN   [58]
RP   VARIANT BLC CANCER GLN-650.
RX   PubMed=11314002; DOI=10.1038/sj.onc.1204110;
RA   Sibley K., Cuthbert-Heavens D., Knowles M.A.;
RT   "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional
RT   cell carcinoma.";
RL   Oncogene 20:686-691(2001).
RN   [59]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=12707965; DOI=10.1002/ajmg.a.10238;
RA   Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V., Francois C.,
RA   Huet F., Couailler J.-F., Campos-Xavier A.B., Bonaventure J., Le Merrer M.;
RT   "Hypochondroplasia and stature within normal limits: another family with an
RT   Asn540-to-Ser mutation in the fibroblast growth factor receptor 3 gene.";
RL   Am. J. Med. Genet. A 119:81-84(2003).
RN   [60]
RP   VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650 AND
RP   MET-650.
RX   PubMed=15772091; DOI=10.1093/hmg/ddi127;
RA   Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A.,
RA   Gasc J.-M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P.,
RA   Radvanyi F.;
RT   "Activating mutations of the tyrosine kinase receptor FGFR3 are associated
RT   with benign skin tumors in mice and humans.";
RL   Hum. Mol. Genet. 14:1153-1160(2005).
RN   [61]
RP   VARIANT CATSHLS HIS-621.
RX   PubMed=17033969; DOI=10.1086/508433;
RA   Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A.,
RA   Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C.,
RA   Bamshad M.J.;
RT   "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing
RT   loss (CATSHL) syndrome.";
RL   Am. J. Hum. Genet. 79:935-941(2006).
RN   [62]
RP   VARIANTS KNEN CYS-248; CYS-370 AND ARG-380.
RX   PubMed=16841094; DOI=10.1172/jci28163;
RA   Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R., Blaszyk H.,
RA   Hofstaedter F., Zwarthoff E.C., Hartmann A.;
RT   "Mosaicism of activating FGFR3 mutations in human skin causes epidermal
RT   nevi.";
RL   J. Clin. Invest. 116:2201-2207(2006).
RN   [63]
RP   VARIANT LADDS ASN-513.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D.,
RA   Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G.,
RA   Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M.,
RA   Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [64]
RP   VARIANT CAN GLU-391.
RX   PubMed=17935505; DOI=10.1111/j.1399-0004.2007.00884.x;
RA   Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.;
RT   "Crouzon with acanthosis nigricans. Further delineation of the syndrome.";
RL   Clin. Genet. 72:405-410(2007).
RN   [65]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384; ASN-646
RP   AND GLU-650.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [66]
RP   VARIANT TGCT GLU-650.
RX   PubMed=19855393; DOI=10.1038/ng.470;
RA   Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K.,
RA   McGowan S.J., Pfeifer S.P., McVean G.A., Rajpert-De Meyts E., Wilkie A.O.;
RT   "Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for
RT   congenital disorders and testicular tumors.";
RL   Nat. Genet. 41:1247-1252(2009).
CC   -!- SUBCELLULAR LOCATION: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=IIIc;
CC         IsoId=P22607-1; Sequence=Displayed;
CC       Name=2; Synonyms=IIIb;
CC         IsoId=P22607-2; Sequence=VSP_002988;
CC       Name=3; Synonyms=FGFR3deltaTM;
CC         IsoId=P22607-3; Sequence=VSP_002989;
CC       Name=4;
CC         IsoId=P22607-4; Sequence=VSP_040945;
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   CCDS; CCDS3354.1; -.
DR   RefSeq; NP_075254.1; NM_022965.3.
DR   ProteomicsDB; 54007; -.
DR   Ensembl; ENST00000352904.6; ENSP00000231803.1; ENSG00000068078.20.
DR   Proteomes; UP000005640; Chromosome 4.
PE   1: Evidence at protein level;
SQ   SEQUENCE   694 AA;  75696 MW;  4493C5990FD68964 CRC64;
     MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS
     CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH
     FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG
     NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT
     YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP
     DGTPYVTVLK VSLESNASMS SNTPLVRIAR LSSGEGPTLA NVSELELPAD PKWELSRARL
     TLGKPLGEGC FGQVVMAEAI GIDKDRAAKP VTVAVKMLKD DATDKDLSDL VSEMEMMKMI
     GKHKNIINLL GACTQGGPLY VLVEYAAKGN LREFLRARRP PGLDYSFDTC KPPEEQLTFK
     DLVSCAYQVA RGMEYLASQK CIHRDLAARN VLVTEDNVMK IADFGLARDV HNLDYYKKTT
     NGRLPVKWMA PEALFDRVYT HQSDVWSFGV LLWEIFTLGG SPYPGIPVEE LFKLLKEGHR
     MDKPANCTHD LYMIMRECWH AAPSQRPTFK QLVEDLDRVL TVTSTDEYLD LSAPFEQYSP
     GGQDTPSSSS SGDDSVFAHD LLPPAPPSSG GSRT
//
